A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Project for Futuristic Surgical Training Receives CHF 12 Million in Funding

Project for Futuristic Surgical Training Receives CHF 12 Million in Funding

Surgical Training: Swiss Innovation Agency Innosuisse has awarded a grant of CHF 12 million over the next four years in support of the “PROFICIENCY” project for surgical simulation. The project initiates a paradigm shift in practical training in surgery: away from primary training in the operating room, towards standardized and proficiency-based surgical training curricula.

Thanks to technical advances in virtual and augmented reality, many surgical procedures can already be simulated with lifelike accuracy. However, practical training still frequently occurs in the operating room. The disadvantage of this form of training became obvious during the Covid 19 pandemic: surgical training was largely restricted or not possible at all in most hospitals during this time.

“With the ‘PROFICIENCY’ project, we want to advance simulator-based continuing education in surgery,” explains Prof. Bruno Schmied, M.D., Chief of Surgery at the Cantonal Hospital of St. Gallen. “The innovative continuing education program – analogous to the training and continuing education of pilots on flight simulators – will decisively improve surgical continuing education in open and minimally invasive surgery and initiate the desired paradigm shift to competence-oriented and didactically high-quality simulator-supported training.”

As a first decisive step, the project will design a modular curriculum that is aligned with the requirements of surgical societies and integrated on a digitally accessible learning platform. This standardized, evidence-based and performance-oriented training program will be taught using the latest didactic methods and empower surgeons to acquire skills through self-paced learning.

In a second major step, the consortium will develop innovative training tools for simulating different surgical scenarios, ranging from online virtual reality simulation, augmented box trainers, high-end simulators, to augmented-reality-enabled open surgery and immersive remote operation room participation.

“This flagship innovation project brings together the necessary medical, pedagogical and technical expertise to create the most advanced and comprehensive surgical training curriculum ever developed,” said Stefan Tuchschmid, PhD, co-CEO and founder of VirtaMed.

The consortium of project partners includes the Cantonal Hospital of St.Gallen, Lausanne University Hospital (CHUV), the University of Zurich with Balgrist University Hospital, ETH Zurich and Zurich University of Applied Sciences (ZHAW), as well as the companies VirtaMed AG, Microsoft Schweiz GmbH , ORamaVR S.A. and Atracsys LLC.

SourceVirtaMed
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy